
GK Daily Special Edition: Psychedelics in Psychiatry — Where the FDA Path Stands After the MDMA Rejection
In August of 2024, the FDA rejected MDMA-assisted therapy for PTSD. Investors fled, the company behind it laid off three quarters of its staff, and commentators wrote obituaries for the entire field. Two years later, psychedelic medicine is closer to approval than it has ever been. We walk through why the advisory committee voted 9-2 against effectiveness — functional unblinding, trial conduct problems, durability questions — and how Compass Pathways designed its psilocybin program to survive exactly that scrutiny, with two positive Phase 3 trials and a rolling NDA finishing this quarter…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.